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Abstract: A two-channel optical system has been developed to provide 
spatially resolved simultaneous imaging of singlet molecular oxygen (
1O2) 
phosphorescence and photosensitizer (PS) fluorescence produced by the 
photodynamic process. The current imaging system uses a spectral 
discrimination method to differentiate the weak 
1O2 phosphorescence that 
peaks near 1.27 μm from PS fluorescence that also occurs in this spectral 
region. The detection limit of 
1O2 emission was determined at a 
concentration of 500 nM benzoporphyrin derivative monoacid (BPD) in 
tissue-like phantoms, and these signals observed were proportional to the PS 
fluorescence. Preliminary in vivo images with tumor laden mice indicate 
that it is possible to obtain simultaneous images of 
1O2 and PS tissue 
distribution. 
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1. Introduction 
Photodynamic therapy (PDT) is a promising cancer treatment. It involves optical excitation of 
photosensitizers that subsequently produces excited singlet molecular oxygen (
1O2) via 
collisional quenching by ground state oxygen molecules within the tumor tissue [1,2]. 
However, the tumor response to PDT treatments is highly variable depending on the 
photosensitizer (PS) concentration in the tumor, treatment light intensity, total light dose 
(fluence), and tumor oxygenation. An accurate dosimeter to optimize the individual treatment 
response of PDT in a clinical environment would be a valuable tool to improve the treatment 
outcomes. A number of groups have attempted to develop dosimeters based on the 
fluorescence intensity of the PS in the tumor [3–5], but the complex dynamics of oxygen-
independent photobleaching of the PS as well as photoproduct formation may preclude this as 
an accurate method without careful calibration for each indication. Optical measurement of 
the 
1O2 phosphorescence produced in tissue would be a more direct way to assess PDT dose to 
the tissue. It is well established that the PDT process consumes oxygen in a manner which can 
substantially deplete the available oxygen supply within tumor tissues [6]. This effect is 
unfavorable for maximal treatment response, as it results in decreased 
1O2 production. It has 
been suggested that maximizing the oxygenation of tissue can enhance PDT efficiency [7]. 
Our imaging system may be able to provide insight into this mechanism. 
During the PDT treatment, oxygen molecules in the metastable singlet delta state, O2(a
1Δ), 
are generated and are believed to be responsible for the destruction of cancer cells [8,9]. The 
1O2 generation is related to the product of the PS concentration [PS], the molecular oxygen 
concentration [O2], and the light dosage Φ(t), i.e. [
1O2] ∝  [PS(t)] [O2] Φ(t) dt. There has been 
considerable interest in developing a sensor for 
1O2 that could be used as a real-time dosimeter 
during PDT treatments [10–15]. Although the measurement of the 
1O2 emission centered near 
1.27 µm has the potential to be an effective technique for evaluating the PDT treatment 
efficacy, monitoring only the 
1O2 production does not distinguish whether the PDT efficacy is 
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we developed a two-dimensional (2D) imaging dosimeter system that enables simultaneous 
imaging of both spatially resolved 
1O2 phosphorescence and PS fluorescence. In 2002, a 
1O2 
image from a→X transition at 1270 nm with a lateral resolution of 2.5 μm was report by 
Andersen et al. [16]. They used a microscope with a custom-made InGaAs linear array. The 
sample was scanned with a movable x-y stage to generate 2D images. Several groups have 
reported 
1O2 images of a single cell and intradermal tumor model in mice by using scanning-
based techniques [17–19]. Since the 
1O2 emission signal is very weak at 1270 nm, chemically 
trapped 
1O2 detection methods in the visible wavelength region have also been reported 
[20,21]. Recently, Hu et al. reported the images of the 
1O2 emission with only using a 1.27 μm 
optical filter with a cooled InGaAs CCD camera with detection limit of ~0.0181 μg/ml BPD-
MA in 75% ethanol [22]. They claimed that a long-pass filter (LP1150) was sufficient to 
achieve spectral discrimination of the 
1O2 emission from other possible radiations, such as PS 
fluorescence, backscattered laser light, and autofluorescence from tissues in vivo. 
The weak optical emission from 
1O2 is one of the major challenges in developing an 
optically-based monitor for this species. We have previously reported on an ultra-sensitive, 
non-imaging sensor with a near-infrared (IR) sensitive photomultiplier tube (PMT) detector 
for 
1O2 measurements both in vitro and in vivo [13–15]. In those studies, a low power, pulsed 
diode laser was used to produce the PDT photoreaction products and the optical emissions 
were detected with a fast photon-counting system. Spectral and temporal discrimination 
techniques were used to isolate the 
1O2 phosphorescence from the PS fluorescence: (1) 
spectral discrimination via a set of three optical filters (1.22, 1.27, and 1.32 μm), and (2) the 
lifetime difference between short-lived PS fluorescence (a lifetime of the order of 10 ns) and 
longer-lived 
1O2 phosphorescence (lifetime of 4 μs in aqueous media and as short as 0.1 μs in 
biological media) [13,14]. The 1.22 and 1.32 µm filters provide a measure of the PS 
fluorescence and possible tissue fluorescence in this near infrared region, while the 1.27 µm 
filter contains underlying continuum PS fluorescence, autofluorescence, and 
1O2 near-IR 
emission. We have successfully detected 
1O2 phosphorescence in tumor laden mice and 
healthy human skin [14,15]. In the animal study, a positive correlation was observed between 
the 
1O2 production and tumor regression. 
In this study, we describe our early continuing progress in the development of the 2D 
imaging configuration to produce spatial maps of the 
1O2 phosphorescence and PS 
fluorescence during PDT. The ability to obtain simultaneous images of both the PS and 
1O2 
will be valuable for assessing the relationship between PS bleaching and 
1O2 production. In 
addition, knowledge of the spatial extent of the tumor sites may help to target the tumor more 
effectively without damaging healthy tissues. We have previously characterized the system 
using  in vitro samples with several photosensitizers (chlorine e6, δ-aminoleuvulinic acid-
induced protoporphyrin IX, and benzoporphyrin derivative monoacid) in several media 
including methanol, water, and fetal bovine serum (FBS), and intralipid solutions as well as 
tumor laden mice [23,24]. Here, we report the results obtained with benzoporphyrin derivative 
monoacid (BPD-MA) photosensitizer in methanol, water, FBS, and intralipid solutions. We 
also present preliminary in vivo images with tumor laden mice. 
2. Methods 
2.1. Dual-channel imaging system configuration 
Figure 1(a) shows a schematic of the 2D imaging system consisting of the excitation diode 
laser, near-IR sensitive camera, and visible wavelength sensitive camera. The imaging system 
is capable of simultaneous registration of images of 
1O2 phosphorescence and PS fluorescence 
in a time frame of a few minutes, compared with typical raster-scanning methods that take 
tens of minutes to map out an entire area of interest. Fast image acquisition becomes critical 
because the PDT treatment needs to be monitored in real-time without compromising the 
detection quality in a clinical environment. Figure 1(b) shows the in vitro configuration to 
characterize the system with deoxygenating capability. The camera viewed the solution 
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solution, nitrogen is slowly bubbled through a sample bottle. This deoxygenation method was 
used to demonstrate that the near-IR camera measures the 
1O2 phosphorescence even in the 
presence of PS fluorescence. 
 
Fig. 1. Singlet oxygen 2D imaging system. (a) The schematic of current 2D imaging system (in 
vivo). (b) Experimental setup of deoxygenating configuration (in vitro). 
A near-IR camera (MOSIR 950, 26.6 × 6.7 mm, 1024 × 256 pixels, 26 × 26 μm pixel size) 
was used for the 
1O2 phosphorescence detection. This camera uses a high quantum efficiency 
photocathode and an electron bombardment intensifier to provide near single-photon detection 
in the 1 to 1.5 μm spectral region. A visible camera (Pike F-145, 9.0 × 6.7 mm, 1392 × 1040 
pixels, 6.45 × 6.45 μm pixel size) was used for the visible PS fluorescence measurement. To 
image entire area of ~1 x 1 cm to the detector, the magnification of the imaging system was 
set for × 0.57. Under these conditions, pixel resolution in the object plane is ~46 μm for the 
near-IR image and ~12 μm for the visible image. The focal length of the dual beam imaging 
system was 55 mm, and collimated light from the image area was split between the IR camera 
and the visible camera through a beam-splitter. 
For the BPD excitation, a fiber coupled diode laser with the wavelength centered at 692 
nm was operated at a repetition rate of 10 kHz with a pulse width of 5 μs with an average 
output power of ~230 mW during each pulse. Each pulse contained only 1.15 μJ. The beam 
size of the excitation laser was 15 mm in diameter at the focal plane of the imager, and an 
optical diffuser was used to generate a uniform excitation spot. At present, the time-gating 
rate of the near-IR camera is insufficient for rapid data accumulation. Therefore, a non-gating 
mode (continuous mode) for the near-IR camera with appropriate spectral background 
subtraction was tested in this study. In the non-gating mode, the camera is focused on the 
fluorescence volume and measures the collected photoelectrons for a preset length of time. 
For the 
1O2 detection, three spectral images were recorded in rapid succession using a 
computer controlled slider containing three bandpass (BP) filters centered at 1.22, 1.27 and 
1.32 µm, each with a full width at half maximum (FWHM) bandwidth of 15 nm. These filters 
were used to spectrally isolate the 
1O2 emission near 1.27 μm from the long wavelength 
spectral background signal, such as PS fluorescence and/or phosphorescence, and 
autofluorescence. The emissions at 1.22 and 1.32 µm (out-of-the band wavelengths) contain 
only PS fluorescence while the emission at 1.27µm contains contributions from both the 
1O2 
and PS as shown in Fig. 2(a) obtained in vitro using BPD (1 μM in methanol). The images 
recorded at 1.22 and 1.32 µm were co-registered and averaged to generate a single spectral 
image of the PS fluorescence. This formed a first order estimate of the signal level of the PS 
fluorescence contribution to the 1.27 µm image. This averaged PS fluorescence image was 
subsequently subtracted on a pixel by pixel basis from the image obtained with the 1.27 µm 
filter. For the visible PS fluorescence detection, a BP filter was selected and placed before the 
visible CCD camera to transmit a specific wavelength region for the PS fluorescence. Each 
bandpass filter was selected for a particular PS to optimize the transmission and spectral 
discrimination. 
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Fig. 2. Singlet oxygen detection method. (a) Temporal profiles (using PMT detector) of 
1O2 
phosphorescence at three bandpass filter positions with 1 μM BPD in methanol. The signal 
during excitation light ON period (6-11 μs) is due primarily to PS fluorescence with 1320 and 
1220 nm filter; or 
1O2 emission and PS fluorescence with 1270 nm filter. The increase in the 
signal with 1270 nm filter is due to increasing 
1O2 production during the excitation pulse. (b) 
Spectral features of 
1O2 phosphorescence and total emission intensity with 1 μM BPD in 
methanol. (c) The method of the 
1O2 image process with the three-filter operation (in vitro). 
To investigate the background signal level more precisely at and near the 
1O2 emission 
band, a liquid crystal tunable filter (Cambridge Research & Instrumentation, Inc., model# 
LNIR-06, FWHM = 6 nm) was used to obtain a detailed spectrum. Figure 2(b) shows how the 
long wavelength (1.2-1.4 µm) PS fluorescence is recorded and subtracted from the entire PDT 
emission spectrum to provide the emission due to the 
1O2. In the current 2D imaging system, 
both 
1O2 phosphorescence and PS fluorescence were collected, as shown in the upper trace of 
the triangle symbols in Fig. 2(b) with three optical filters centered at 1.22, 1.27 and 1.32 μm. 
The shaded areas under A, B, and C in Fig. 2(b) represent the total light intensities that were 
measured for the out-of-the band baseline signals (A and C) and in-band signal of 
1O2 
intensity and baseline contribution (B). By subtracting the average baseline signal (average 
value of A and C) from the signal B, the 
1O2 intensity was calculated. This spectral 
discrimination approach is essential to distinguish the 
1O2 emission from other long 
wavelength background signals, as mentioned above. Hu et al. measured the 2D images of 
1O2 
emission using a 1.27 μm optical filter with a long-pass filter (LP1150) [22]. As shown in Fig. 
2(b), a single long-pass filter with a 1.27 μm filter is not able to robustly differentiate 
1O2 
phosphorescence from other long wavelength background signals. This is especially true for 
in vivo measurements where the 
1O2 phosphorescence is typically weak relative to the 
underlying fluorescence background. 
Figure 2(c) shows an example of how the images of 
1O2 phosphorescence were acquired. 
The diode laser beam was directed onto the face of a 1 cm square cuvette which contained 50 
μM chlorine e6 (Cl-e6) in phosphate buffer solution. The pixel by pixel averaged values of the 
1.22 and 1.32 µm images was subtracted from the image recorded at 1.27 µm to produce the 
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1O2 phosphorescence. Note that it takes typically less than 30 sec with in vitro 
samples. In this example, dark count subtraction of each image before calculating the 
1O2 
intensity is not shown. The dark count subtraction for each image is an essential step to 
improve S/N with in vivo image quality. 
The spatial resolutions of both the visible and near-IR imaging systems were measured 
using a standard Air Force test pattern as shown in Fig. 3. This imaging system was developed 
to image the entire area of light illumination, ~1 × 1 cm. Therefore the magnification of the 
imaging system considering physical size of detectors was optimized to image the entire area 
to the detector as × 0.57 for both cameras. The respective spatial resolutions for the visible 
and near-IR systems were <30 μm and <100 μm empirically estimated based on a FWHM 
limit of a line spread function method. 
 
Fig. 3. Image resolution of the dual-channel system. (a) Visible image. (b) NIR image. 
2.2. In vitro and in vivo experiments 
1O2 phosphorescence imaging from BPD in methanol, water, FBS, and intralipid solutions 
was investigated in order to determine the detection sensitivity. The solvents were used to 
provide a variety of quenching environments. Since the lifetimes of 
1O2 are known in these 
solvents, they provided an excellent test of our system. BPD solutions were procured from 
U.S. Pharmacopeia (Verteporfin) and solvents from Fisher Scientific. BPD concentrations 
covering the range 10
−4 to 10
−6 molar were prepared. All mixed BPD solutions were kept in 
amber glass bottles to minimize any interactions with room lights. 
A preliminary study of 
1O2 production during PDT in tumor laden mice was also 
conducted. The BPD photosensitizer is commonly used for treatment of age related macular 
degeneration [25], and has been initiated in studies for solid pancreatic tumors [26]. However, 
the 
1O2 generation of BPD is not as well studied as Cl-e6 or δ-aminoleuvulinic acid-induced 
protoporphyrin IX (ALA-induced PpIX). We have previously reported results using these 
latter photosensitizers [23,24]. All animal procedures were carried out according to protocols 
approved by the Dartmouth College Institutional Animal Care and Use Committee (IACUC). 
Pancreatic tumor cells were implanted subcutaneously in 6-week-old male nude mice (~22g). 
AsPC-1 cells, derived from a human pancreatic acinar cell adenocarcinoma (CRL-1682, 
American Type Culture Collection (ATCC), Manassas, VA 20108) were cultured in RPMI 
1640 with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin-streptomycin prepared for 
a stock solution of 10,000 IU penicillin and 10,000 g/ml streptomycin (Mediatech Herndon, 
Virginia), 2mM L-glutamine, 10 mM HEPES, 1mM sodium pyruvate, 4500mg/L glucose, and 
1500mg/L sodium bicarbonate. The cells were passed by washing twice with phosphate buffer 
solution (PBS) without calcium and magnesium and then incubated at 37°C with 0.25% 
trypsin for 5-10 minutes. When all the cells had lifted off from the bottom of the culture flask, 
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suspended in complete medium at 4x10
7 cells/ml. 
The cells, required for implantation, were prepared in a 1:1 mixture of cell culture medium 
and Matrigel® (BD Biosciences, San Jose, CA). Matrigel® was thawed on ice in a 4°C 
refrigerator overnight and was kept on ice for the entire implantation procedure. AsPC-1 cells 
were diluted in a 1:1 ratio of culture medium and Matrigel® to a final concentration of 4x10
7 
cells/ml for implantation. Sterile insulin syringes (1⁄2 cc U-100 Lo-Dose Insulin Syringe 
281⁄2, Becton Dickinson & Co., Franklin Lakes, NJ) were loaded with the cell-Matrigel® 
solution and placed and kept on ice ready for the implantation procedure. 
Once the mouse was sedated using isoflurane gas (O2 flow meter set to 1L/min; induction 
at 3% then reduced to 1.5-2%), the left side of the mouse’s abdomen was sterilized with an 
iodine solution (Povidone-Iodine, Novaplus, Irving, TX) and the cell-Matrigel® solution 
(1x10
6 cell in 50µl) was injected subcutaneously. The Matrigel® was allowed to set (~10 
seconds) and the needle was gently removed from the injection site and swabbed with iodine 
to kill any stray cells in the injection site. The growth of the AsPC-1 tumors in each mouse 
was measured daily, using calipers, up to two weeks after implantation so that an average 
tumor volume of approximately 90mm
3 was reached for the in vivo BPD study. 
BPD doses of 0.5, 1, and 2 mg / body weight kg were used for this part of the study. 
Verteporfin for injection was obtained from QLT Inc. (Vancouver, Canada) as a gift. 
Verteporfin for injection is composed of a sterile liposomal formulation of BPD-MA 
(Visudyne, Novartis, New York). A stock saline solution of Verteporfin was reconstituted in 
water according to the manufacturer’s guidelines, using 2.5% as the active component. 
Animals were injected intravenously, via the lateral tail vein, with 75ul of Verteporfin to 
achieve the required dose of 0.5, 1 or 2 mg/kg body weight. 
After one hour to allow for systemic tissue distribution and uptake within the tissue 
organs, the mouse was anesthetized for in vivo imaging. Gas anesthesia is the preferred 
method of immobilization for in vivo imaging of mice and rats and isoflurane gas is minimally 
metabolized (<0.17%) by the liver and therefore is less toxic to the animal’s metabolism as 
compared to injectable anesthetics. Once the mouse was sedated, the skin around the tumor 
was carefully cut and drawn back to expose the tumor tissue situated subcutaneously. The 
mouse was transferred to the imaging platform of the dual-channel imaging system and placed 
in position so that its nose was in front of the nose cone attached to the isoflurane anesthesia 
system. The imaging system platform has an electric heat pad integrated in order to keep 
animals warm during anesthesia in order to prevent hypothermia. Once the ideal position had 
been achieved, images of BPD fluorescence and 
1O2 phosphorescence were acquired using the 
visible and near-IR cameras respectively. Each mouse took approximately 10 minutes to 
image. After the tumor side was imaged, the skin on the contralateral side of the mouse was 
removed and normal tissue was imaged for comparison. Following the completion of imaging, 
the anesthetized mouse was euthanized by cervical dislocation. 
3. Results and discussion 
To characterize the imaging system, a series of in vitro studies were conducted with the BPD 
photosensitizer in several media including protein-laden aqueous solutions that are significant 
quenchers of 
1O2. Figure 4(a) shows the spatially resolved images of both the 
1O2 
phosphorescence (right panel) and BPD fluorescence (left panel) in methanol recorded for 10 
seconds through each of the three optical filters. To verify that this signal originates from 
1O2, 
nitrogen gas was bubbled through the sample bottle to displace the dissolved oxygen with the 
configuration shown in Fig. 1(b). When the solution was deoxygenated as shown in Fig. 4(b), 
the 
1O2 phosphorescence signal diminished significantly. The intensities of the 
1O2 
phosphorescence and BPD fluorescence were summed within the illumination areas (marked 
with a square box in the images) as shown in Fig. 4(c). The total photoelectron counts from 
the 
1O2 phosphorescence decreased more than 90% when the sample was deoxygenated. In 
contrast, the BPD photosensitizer fluorescence remained essentially constant. These   
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Fig. 4. Spatially resolved images (10 μM BPD in methanol). (a) Ambient air saturated. (b) 
Deoxygenated solutions (nitrogen gas purging through the solution). (c) Total BPD 
fluorescence and singlet O2 phosphorescence intensities in the area of the interest marked with 
a square box in the images of 5 × 5 mm. 
observations support our conclusion that the additional signal at 1270 nm we observed when 
oxygen is present is from 
1O2 phosphorescence. 
Figure 5 shows the plot of both the 
1O2 phosphorescence and BPD fluorescence intensities 
(from spatially resolved images) as functions of the BPD concentration in a highly quenching 
FBS environment. For comparison, the signal intensity of the 
1O2 phosphorescence in 5% FBS 
solutions was ~20 times lower than that in methanol solutions. These data were obtained in 
40-50 seconds at each optical filter position to increase signal-to-noise level. There is a strong  
 
 
Fig. 5. Plot of singlet O2 phosphorescence and BPD fluorescence as a function of BPD 
concentration in 5% FBS with 5% TTX-100. Note that the intensities of PS fluorescence and 
singlet O2 phosphorescence are not normalized with respect to the signal accumulation 
conditions of the different camera settings. 
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1O2 and the PS fluorescence. Spatially resolved images 
of the 
1O2 phosphorescence and the PS fluorescence were obtained with the BPD 
concentration as low as 500 nM (0.355 μg/ml) in FBS solution as well as in a highly scattering 
environment using 2-5% intralipid solution. These concentrations are relevant to in vivo 
applications and indicated that we might observe images of 
1O2 phosphorescence in tumor 
models. For comparison, a detection limit of 100 nM (0.071 μg/ml) was determined in 
methanol solution (less quenching environment). These detection limits were determined with 
the PS baseline subtraction to estimate 
1O2 signal level. 
Simultaneous, spatially resolved images were recorded for both the BPD fluorescence and 
1O2 phosphorescence with tumor laden mice. Both images from two mice with tumors 
implanted are shown in Fig. 6 with 0.5 and 1 BPD mg/ body kg administered one hour prior to 
imaging. We did not observe any selective localization of BPD photosensitizer in the AsPC-1 
tumors vs. normal tissues, similar to that reported by O’Hara et al. [27]. These particular 
images were recorded with the skin removed at the tumor sites. The BPD photosensitizer 
accumulation in the AsPC-1 pancreatic model has been a challenge for these preliminary 
experiments because of the lack of extensive vascular structure and considerable stroma 
associated with this tumor model. The low concentration of BPD in tumor sites was confirmed 
with separate BPD fluorescence measurements. Much stronger PS and 
1O2 signals were 
observed in earlier animal studies that we reported on, using Cl-e6 photosensitizer with 
prostate tumor laden mice [23,24]. 
Even with a low 
1O2 production condition caused by low BPD concentration in tumor 
sites, we have obtained spatially correlated images of BPD fluorescence and 
1O2 
phosphorescence using our image data reduction algorithms described in the Methods section. 
Some of the spatial features are common in both the PS and 
1O2 images. In addition, the 
spatial profiles of the intensities for the two species differ indicating that the 
1O2 and PS 
spatial profiles may be distinct. The noise in the near-IR 
1O2 image is due to the relatively 
small signal remaining subsequent to the data reduction algorithm that removes the near-IR 
PS fluorescence background. Currently, we utilize a simple linear fit to estimate the PS 
fluorescence baseline under the 
1O2 phosphorescence spectral feature. However, the linear 
baseline subtraction is clearly a first-order approximation. While this approximation appears 
to work fairly well for lower quenching and scattering environments, we have seen 
preliminary evidence that suggests this simple assumption may not be adequate with highly 
quenching/scattering environments. For example, we observed that long wavelength   
 
 
Fig. 6. Images of the BPD fluorescence and singlet oxygen phosphorescence from two tumor 
laden mice. (a) 1.0 mg BPD / body kg. (b) 0.5 mg BPD / body kg. 
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We will further investigate the long wavelength baseline component in this near-IR region to 
improve the spectral discrimination method especially within in vivo environments. In 
addition, once the system is optimized for PS fluorescence and 
1O2 emission, our plan is to 
calibrate the entire system using a blackbody source to determine its absolute spectral radiant 
responsivity of each imaging channel. Recently, we also obtained spatially resolved images of 
1O2 phosphorescence and PS fluorescence using Cl-e6 with tumor laden mice in less than 3 
minutes of data acquisition and these results will be reported in the near future. 
4. Conclusion 
We have described a dual-channel imaging system for simultaneous measurements of 
1O2 
phosphorescence and PS fluorescence for PDT. The current imaging system enabled direct 
spatially resolved measurements of both the 
1O2 and PS concentrations produced during PDT. 
We performed sensitive in vitro measurements and obtained initial simultaneous images of the 
1O2 and PS from tumors in two mice. These results are promising for the development of a 
real-time imaging dosimeter for PDT. 
The 2D imaging system has the potential to facilitate a greater understanding of the 
kinetics involved in PDT mechanisms, the relationship between 
1O2 production and 
photobleaching of the PS, and for developing more effective treatment modalities. An 
accurate real-time dosimeter to characterize and optimize the individual treatment response of 
PDT in a clinical environment would be an important tool to improve PDT efficacy. The dual-
channel imaging system may enable us not only to target a specific area of PS in tumor sites 
more precisely by monitoring PS fluorescence, but also to monitor the 
1O2 production which 
is an indication of tumor killing power during the PDT treatment. Eventually, it may even be 
possible to measure the local singlet oxygen dose delivered to tissue during PDT and use such 
dosimetry to improve therapeutic outcomes. 
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